Breakthrough in Lung Cancer Treatment: Ivonescimab Delivers Positive Overall Survival Results at WCLC 2026

Ivonescimab is a first-in-class bispecific antibody that simultaneously targets Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor A (VEGF-A) to restore immune clearance while dismantling tumor blood supplies.

The clinical landscape of thoracic oncology reached a transformative milestone at the 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, South Korea. Researchers unveiled definitive overall survival (OS) data from the Phase 3 HARMONi-2 trial, demonstrating that ivonescimab monotherapy significantly outperforms pembrolizumab in first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC). Presented by Lead Investigator Professor Caicun Zhou, the findings establish a compelling precedent for bispecific antibodies as the next evolutionary step in targeted immuno-oncology.

Understanding Ivonescimab: A Next-Generation Bispecific Molecule

Ivonescimab (AK112/SMT112) is a tetravalent bispecific antibody engineered to deliver dual immunomodulatory and anti-angiogenic activity through a single molecular structure.

Unlike traditional therapeutic approaches that rely on combination regimens consisting of two separate drugs, ivonescimab features a cooperative binding architecture. By physically joining an anti-PD-1 domain with an anti-VEGF-A domain, the molecule concentrates heavily within the tumor microenvironment (TME) where both targets are abundant. This dual action accomplishes two critical anti-cancer goals concurrently:

1. Reactivating T-Cell Function: Blocks the PD-1 immune checkpoint, turning off the inhibitory signals that cancer cells use to hide from T-cells.
2. Starving Tumor Blood Supply: Neutralizes VEGF-A, halting neo-angiogenesis and normalizing abnormal tumor blood vessels to enhance T-cell infiltration.

+-----------------------------------------------------------------------+
|                         IVONESCIMAB MECHANISM                         |
+-----------------------------------+-----------------------------------+
|          PD-1 INHIBITION          |         VEGF-A INHIBITION         |
+-----------------------------------+-----------------------------------+
| • Reverses cytotoxic T-cell       | • Blocks neo-vascularization      |
|   exhaustion                      | • Normalizes tumor blood vessels   |
| • Restores immune detection       | • Reduces local immunosuppression |
+-----------------------------------+-----------------------------------+
                                    |
                                    v
+-----------------------------------------------------------------------+
|                 SYNERGISTIC TUMOR MICROENVIRONMENT CLEARANCE          |
+-----------------------------------------------------------------------+

The Unmet Need in Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) constitutes approximately 85% of all global lung cancer diagnoses, remaining the primary cause of cancer death worldwide.

While immune checkpoint inhibitors targeting PD-1 or PD-L1 transformed first-line care over the past decade, a major clinical challenge persists: primary and acquired resistance. A substantial portion of patients receiving single-agent immunotherapies experience disease progression within twelve months of initiating therapy.

Tumor blood vessels generated through overexpression of VEGF play a direct role in driving this therapeutic resistance. Abnormally formed tumor vasculature creates a high-pressure, hypoxic microenvironment that prevents T-cells from invading tumor tissue. Furthermore, VEGF actively suppresses immune cell maturation. Simply blocking PD-1 leaves this physical and chemical anti-immune shield intact. Overcoming this barrier requires a strategy that strips away the tumor's defense mechanisms without causing unacceptable patient toxicity.

Dual-Targeting Science: The Bi-Functional Advantage

Dual-targeting bispecific therapy combines immune checkpoint blockade with vascular normalization to generate synergistic anti-tumor responses.

Traditional clinical strategies attempting to combine separate anti-PD-1 and anti-VEGF systemic medications frequently encountered dose-limiting toxicities, particularly severe bleeding, hypertension, and proteinuria. Ivonescimab circumvents these systemic toxicity challenges through cooperative binding kinetics.

PD-1/PD-L1 Checkpoint Recovery

The interaction between PD-1 on immune T-cells and PD-L1 on cancer cells acts as a brake on the immune response. By occupying the PD-1 receptor site, ivonescimab releases this brake, prompting cytotoxic lymphocytes to recognize, attack, and eliminate malignant cells.

VEGF Inhibition and Vascular Normalization

Tumors secrete VEGF-A to force the rapid growth of new capillaries. These blood vessels are structurally defective, leaky, and disorganized, impairing normal blood flow and creating an acidic, immunosuppressive sanctuary for tumor growth. By binding VEGF-A, ivonescimab prunes away dysfunctional capillaries and normalizes the remaining vasculature, facilitating T-cell transit directly into the tumor core.

The "1+1 > 2" Synergistic Effect

Binding to VEGF-A actually increases ivonescimab's affinity for PD-1 on surrounding cells. This cooperative binding concentrates the antibody directly at the active tumor site, maximizing local therapeutic pressure while minimizing off-target exposure in healthy tissue.

WCLC 2026: Phase 3 HARMONi-2 Overall Survival Findings

The HARMONi-2 trial (AK112-303) is a randomized, head-to-head Phase 3 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in first-line PD-L1-positive NSCLC.

Conducted across leading clinical centers, the study enrolled patients with locally advanced or metastatic NSCLC exhibiting a PD-L1 Tumor Proportion Score (TPS) of 1% or higher, excluding tumors with actionability through EGFR or ALK genomic alterations.

Primary Survival Outcomes

At the median follow-up mark of 36 months, ivonescimab demonstrated a statistically significant and clinically transformative improvement in overall survival compared to standard-of-care pembrolizumab.

Data cutoff: August 20, 2026. Median follow-up period: 36 months.

The survival curves exhibited early separation that continued to widen over time, confirming sustained long-term clinical benefits.

ESTIMATED OVERALL SURVIVAL RATES (HARMONi-2)

Ivonescimab   [==================== 57.9% @ 2 Yrs ====================] 45.0% @ 3 Yrs
Pembrolizumab [=============== 48.0% @ 2 Yrs ===============] 33.1% @ 3 Yrs
              0%        20%       40%       60%       80%      100%

Subgroup Survival Performance

Ivonescimab demonstrated broad superiority across prespecified patient populations, regardless of tissue histology or tumor biomarker levels.

Patients with high PD-L1 expression (TPS ≥50%) achieved exceptional survival benefits, with median overall survival not yet reached at the time of analysis. This subgroup demonstrated a 42% reduction in the risk of death compared to pembrolizumab monotherapy.

Safety Profile and Tolerability

Despite dual pathway targeting, ivonescimab maintained a favorable safety profile comparable to single-agent anti-PD-1 therapy.

• Treatment-Related Adverse Events (TRAEs): Any-grade TRAEs occurred in 93.4% of ivonescimab patients versus 84.9% of pembrolizumab patients.
• Grade 3 or Higher TRAEs: Severe adverse events occurred in 29.9% of the ivonescimab cohort compared to 21.6% in the pembrolizumab arm.
• Discontinuation Rates: Treatment discontinuation rates driven by adverse events remained low and balanced (4.1% for ivonescimab vs. 5.0% for pembrolizumab).
• Immune-Mediated Events: Immune-related adverse event rates were virtually identical between arms (34.0% vs. 33.7%).

Importantly, traditional anti-VEGF safety concerns—such as severe hemoptysis, major arterial bleeding, and unmanageable hypertension—were minimal, even among patients with squamous cell carcinoma.

Expert Insights and Clinical Significance

Leading clinical investigators and oncology leaders evaluated the practical implications of the WCLC 2026 survival data:

"The definitive overall survival results from the HARMONi-2 trial mark a turning point in the management of advanced non-small cell lung cancer," noted Professor Caicun Zhou, Principal Investigator of the trial, IASLC President, and Director of the Department of Oncology at Shanghai East Hospital. "Demonstrating a significant overall survival advantage over monotherapy pembrolizumab confirms that dual bispecific targeting represents a superior therapeutic strategy for this patient population."

"These robust overall survival figures substantiate the mechanism of cooperative bispecific inhibition," stated Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics. "The clinical outcome validates our conviction that targeting PD-1 and VEGF simultaneously via a single molecule represents a transformative approach for first-line cancer treatment globally."

Dr. Michelle Xia, Chief Executive Officer of Akeso, emphasized: "Ivonescimab's performance establishes a new benchmark across the landscape of immuno-oncology. These data confirm that engineering smart bispecific constructs can significantly surpass established mono-target immunotherapies."

Global Clinical Development and Regulatory Horizon

Following its initial regulatory approval in China in early 2025 based on progression-free survival metrics, ivonescimab is undergoing comprehensive global evaluation across several ongoing Phase 3 trials:

• HARMONi-7 Trial: Evaluating ivonescimab monotherapy directly against pembrolizumab monotherapy in non-small cell lung cancer patients exhibiting high PD-L1 expression levels (TPS ≥50%).
• HARMONi-3 Trial: Investigating ivonescimab in combination with platinum-doublet chemotherapy for first-line metastatic squamous and non-squamous NSCLC.
• HARMONi-A / HARMONi Studies: Testing the drug in patients who developed disease progression following prior EGFR tyrosine kinase inhibitor (TKI) treatments.
• Broad Solid Tumor Program: Expanding clinical investigations into triple-negative breast cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, and urothelial carcinoma.

The overall survival data presented at WCLC 2026 provides a robust foundation for global regulatory submissions across North America, Europe, and Asia, positioning ivonescimab to establish a new global standard of care.

Frequently Asked Questions

How does Ivonescimab differ from existing anti-PD-1 lung cancer therapies?

Ivonescimab is a single bispecific antibody engineered to target both PD-1 and VEGF-A simultaneously. Standard immunotherapies like pembrolizumab target only the PD-1 immune checkpoint. Ivonescimab combines checkpoint blockade with vascular normalization, enhancing drug concentration at the tumor site and generating superior overall survival outcomes compared to single-agent immunotherapy.

Which lung cancer patient groups showed the greatest survival benefit in the HARMONi-2 trial?

While overall survival improved across all studied subgroups, the benefit was most pronounced in patients with high PD-L1 expression (TPS ≥50%), where median overall survival was not yet reached, representing a 42% risk reduction versus pembrolizumab. Patients with squamous cell carcinoma also experienced notable improvements, achieving a median overall survival of 30.5 months versus 19.3 months.

Does combining anti-VEGF and anti-PD-1 mechanisms in Ivonescimab increase toxic side effects?

Clinical trial data demonstrate that ivonescimab maintains a manageable safety profile comparable to single-agent immunotherapy. Treatment discontinuation rates due to side effects were low (4.1% for ivonescimab versus 5.0% for pembrolizumab). The bispecific design concentrates anti-VEGF activity directly in tumor tissue, avoiding the high systemic toxicity risks previously associated with combining separate anti-angiogenic drugs and immunotherapies.

What is the current global availability status of Ivonescimab?

Ivonescimab received regulatory approval in China in 2025 for advanced PD-L1-positive non-small cell lung cancer based on initial progression-free survival results. Global Phase 3 studies, including the HARMONi-3 and HARMONi-7 trials, are underway to support regulatory approval submissions with the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Featured image by Aakash Dhage on Unsplash